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S U M M A R Y
Background: Clostridium difﬁcile is a major infectious cause of healthcare-associated diarrhea. The
epidemiology of C. difﬁcile infection (CDI) is changing, with evidence of increased incidence and severity.
The ﬁrst patient with a hypervirulent strain type in Pirkanmaa Hospital District, Finland was reported in
September 2008.
Methods: We reviewed all culture-positive C. difﬁcile episodes that occurred in Pirkanmaa Hospital
District during the period September 2008 to May 2010.
Results: A total of 780 episodes of C. difﬁcile occurred in 622 patients. A hypervirulent strain caused 14.2%
of all episodes. The day 30 case fatality associated with CDI was 8.5% in episodes with a non-
hypervirulent strain and 20.7% in episodes with a hypervirulent strain type (p < 0.001, odds ratio 2.8,
95% conﬁdence interval 1.6–4.8). The median age among those infected by a hypervirulent strain was
higher than among those infected by a non-hypervirulent strain (83 vs. 75 years, p < 0.001).
Hypervirulent strain type remained a signiﬁcant factor associated with case fatality in a logistic
regression model. Blood leukocytes were signiﬁcantly higher in episodes due to a hypervirulent strain
(11.0 vs. 9.4  109/l, p = 0.007). Blood leukocytes and C-reactive protein (CRP) on the day of diagnosis
were signiﬁcantly higher in non-survivors compared to survivors in CDI (13.2 vs. 9.6  109/l, p = 0.009,
and 106.0 vs. 79.4 mg/l, p < 0.001, respectively).
Conclusions: Infection due to a hypervirulent strain is a factor associated with increased case fatality in
CDI. Blood leukocytes are signiﬁcantly higher in CDI caused by a hypervirulent strain. Leukocyte count
and CRP are useful prognostic biomarkers in patients with CDI.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Clostridium difﬁcile is a leading infectious cause of healthcare-
associated diarrhea. Several countries have reported increased
C. difﬁcile infections (CDI) and outbreaks, which have been attributed
to the emergence of hypervirulent strains.1–3 CDI ranges from mild
diarrhea to severe diarrhea, shock, paralytic ileus, pseudomem-
branous colitis, toxic megacolon, and death. The treatment options
for severe CDI have been limited so far. However, several novel
therapies for CDI are now at different stages of development.4
There has been an increase in the morbidity, mortality, and
economic burden associated with CDI.1 A few studies have* Corresponding author. Tel.: +358 50 5603081/+358 3 31165111.
E-mail address: Reetta.Huttunen@uta.ﬁ (R. Huttunen).
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http://dx.doi.org/10.1016/j.ijid.2012.02.019examined the role of hypervirulent C. difﬁcile strain type as a
predictor of outcome in this condition. In some studies, CDI due to
hypervirulent strain types has been associated with a signiﬁcantly
increased case fatality rate,5,6 although not all investigations have
conﬁrmed this.2,7 The emergence of toxigenic strains is a major
concern in healthcare facilities, and affects elderly and immuno-
compromised patients in particular.6 Advanced age has been
shown to be a major risk factor for fatal CDI.6,8 However, Miller
et al. indicated that infection due to a hypervirulent strain would
constitute an independent risk factor for mortality after adjusting
for patient age.6 Early prognostic stratiﬁcation of patients with
infectious diseases is a major challenge, and is necessary in order to
target therapeutic strategies efﬁciently. Thus, biomarkers may
offer important information to clinicians.
We retrospectively reviewed all culture-positive episodes of
C. difﬁcile after the emergence of the ﬁrst case of a hypervirulentses. Published by Elsevier Ltd. All rights reserved.
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outcomes in patients infected with a hypervirulent strain to those
of patients infected with a non-hypervirulent one. We also
assessed the prognostic value of basic laboratory markers in
CDI. We determined that hypervirulent strain and advanced age
were factors associated with increased case fatality in CDI, and that
leukocyte count and C-reactive protein (CRP) are useful prognostic
biomarkers in patients with CDI.
2. Methods
2.1. Pirkanmaa Hospital District
The Pirkanmaa Hospital District is a joint municipal authority
comprising 22 municipalities and is responsible for the healthcare
services of about 477 600 inhabitants (population in year 2009).
The overall population of Finland in 2009 was 5 351 427. Thus,
Pirkanmaa Hospital District covers the health care of approxi-
mately 9% of the total Finnish population.9
2.2. Culture-positive Clostridium difﬁcile episodes
We searched the laboratory database of the Centre for
Laboratory Medicine, Pirkanmaa Hospital District, Tampere, for
all patients with cultures positive for C. difﬁcile detected in
Pirkanmaa Hospital District during the period September 10, 2008
to May 26, 2010. In Pirkanmaa Hospital District C. difﬁcile cultures
are performed only for those patients with signs and/or symptoms
of C. difﬁcile (diarrhea and/or pseudomembranous colitis or toxic
megacolon). Asymptomatic carriers are not sought or tested.
Demographic characteristics including age and sex were recorded.
Underlying conditions were also recorded; data were available for
157 episodes. Only patients aged 16 years were included.
Patients with multiple positive cultures for C. difﬁcile were also
recorded, and episodes were considered as separate episodes if the
subsequent culture positivity was detected 15 days after the
previous one. Day 7, day 14, day 30, and day 90 case fatalityTable 1
Characteristics of the study population. All culture-positive episodes of Clostridium difﬁ






Male sex 283 (36.3%) 243
Age, years 77 (63–86) 75
Age >65 years 559 (71.7%) 457
Atherosclerosisb 45 (28.7%) 31
Coronary artery diseaseb 43 (27.4%) 35
Diabetesb 31 (19.7%) 25
Cancerb 36 (22.9%) 34
Dementiab 30 (19.1%) 25
COPDb 12 (7.6%) 11
At least one chronic diseaseb 146 (93.0%) 125
Case fatality
Age in deceased patients (day 30 case fatality) 82 (75.7–8.8) 82
Day 7 case fatality 34 (4.4%) 24
Day 14 case fatality 53 (6.8%) 41
Day 30 case fatality 80 (10.2%) 57
Day 90 case fatality 145 (18.6%) 112
Laboratory parameters (day 0)c
CRP, mg/l (n = 399) 82.2 (3.0–132.3) 82
Blood leukocytes, 109/l (n = 382) 9.8 (7.0–14.7) 9
Plasma creatinine, mmol/l (n = 319) 79 (61–117) 83
Blood platelets, 109/l (n = 382) 269 (199–353) 270
OR, odds ratio; 95% CI, 95% conﬁdence interval; COPD, chronic obstructive pulmonary 
a The p-value indicates the difference between groups of patients infected with a no
b Data available for 157 patients; 136 with a non-hypervirulent strain and 21 with 
c Measured on the day of positive culture for Clostridium difﬁcile.following positive culture for C. difﬁcile was studied using the
Finnish Population Register Centre database.
2.3. Laboratory tests
Stool samples were cultured on selective cycloserine–
cefoxitin–egg yolk–fructose agar (CCFA) broth medium plates,
and typical colonies for C. difﬁcile were identiﬁed 2 days later.
Antimicrobial sensitivity testing to penicillin, clindamycin, vanco-
mycin, metronidazole, and moxiﬂoxacin was done for all strains.
Since resistance to moxiﬂoxacin is typical for C. difﬁcile hyperviru-
lent strain ribotype 027,10 which was the prevailing hypervirulent
strain in Finland during the study period,8 the hypervirulence test
was carried out for all moxiﬂoxacin-resistant strains, either by in-
house PCR11 or by GeneXpert test (Cepheid, Sunnyvale, CA, USA).
Other laboratory tests included were plasma CRP (mg/l; data
available for 399 patients), plasma creatinine (mmol/l; data
available for 319 patients), blood platelets (109/l; data available
for 382 patients), and leukocytes (109/l; data available for
382 patients). Day 0 (culture day) values were recorded.
2.4. Statistical methods
SPSS statistical software package (version 7.5/10) was used for
the statistical analyses, and a two-sided p-value of <0.05 was taken
as the cut-off for statistical signiﬁcance. Categorical data were
analyzed by Chi-square test or Fisher’s exact test as appropriate,
and non-parametric data by Mann–Whitney U-test or Kruskal–
Wallis test. A logistic regression model was used to study the
independent effect of hypervirulent strain type on mortality
models adjusted for potential confounders. Odds ratios (ORs) were
expressed with their 95% conﬁdence intervals (CI).
3. Results
Seven hundred and eighty episodes in 622 patients were detected
during the study period. One hundred and eleven episodes (14.2% of
all isolates) were caused by a hypervirulent strain and 669 episodescile in Pirkanmaa Hospital District from September 10, 2008 to May 26, 2010 were
-hypervirulent
in (n = 669)
Hypervirulent
strain (n = 111)
OR (95% CI) p-Valuea
 (36.3%) 40 (36.0%) 1.0 (0.7–1.5) 0.938
 (61–85) 83 (77–88) <0.001
 (68.3%) 102 (91.9%) 5.3 (2.6–10.6) <0.001
 (22.8%) 14 (66.7%) 6.8 (2.5–18.3) <0.001
 (25.7%) 8 (38.1%) 1.8 (0.7–4.6) 0.237
 (18.4%) 6 (28.6%) 1.8 (0.6–5.0) 0.275
 (25%) 2 (9.5%) 0.3 (0.1–1.4) 0.116
 (18.4%) 5 (23.8%) 1.4 (0.5–4.1) 0.556
 (8.1%) 1 (4.8%) 0.6 (0.1–4.6) 1.0
 (91.9%) 21 (100%) 1.2 (1.1–1.2) 0.362
 (76.0–88.9) 82 (77.0–88.1) 0.811
 (3.6%) 10 (9%) 2.7 (1.2–5.7) 0.009
 (6.1%) 12 (10.8%) 1.9 (0.9–3.7) 0.069
 (8.5%) 23 (20.7%) 2.8 (1.6–4.8) <0.001
 (16.7%) 33 (29.7%) 2.1 (1.3–3.3) 0.01
.4 (31.5–137.5) 79.3 (38.8–126.7) 0.561
.4 (6.7–14.3) 11.0 (8.8–16.9) 0.007
 (61–117) 79 (57.5–108) 0.691
 (195–350) 265 (209–370) 0.231
disease; CRP, C-reactive protein.
n-hypervirulent strain type compared to a hypervirulent strain type.
a hypervirulent strain.
Table 2
Age-speciﬁc all-cause day 30 case fatality in Clostridium difﬁcile infection.
Age group, years Hypervirulent strain (n = 111) Non-hypervirulent strain (n = 669) OR (95% CI) p-Valuea
<65 2 (22.2%) 5 (2.4%) 11.9 (1.9–72.0) 0.028
65 to 74 4 (25%) 6 (5.8%) 5.4 (1.3–22.1) 0.028
>74 to 86 9 (19.6%) 26 (12.4%) 1.7 (0.7–4.0) 0.236
>86 8 (20%) 20 (13.9%) 1.6 (0.6–3.8) 0.341
OR, odds ratio; 95% CI, 95% conﬁdence interval.
a p-Value indicates the difference between groups of patients infected with a non-hypervirulent strain type compared to a hypervirulent strain type.
Table 3
Logistic regression model of the factors associated with day 30 case fatality in
Clostridium difﬁcile infection.
Variable OR (95% CI) p-Value
Hypervirulent strain 4.6 (1.4–15.0) 0.01
Age >75 yearsa 1.5 (0.5–4.9) 0.496
Male sex 1.7 (0.6–4.9) 0.361
Atherosclerosisb 2.4 (0.8–7.2) 0.134
OR, odds ratio; 95% CI, 95% conﬁdence interval.
a Age remained a signiﬁcant factor associated with mortality if atherosclerosis
variable was not included in the model (continuous variable or age >75 years).
b Data available for 157 patients; 136 with a non-hypervirulent strain and 21
with a hypervirulent strain.
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of patients was 77 years (range 17–100 years). Age among those
infected with a hypervirulent strain was higher than in those
infected with a non-hypervirulent strain (median 83 vs. 75 years,
p < 0.001). The majority of patients (>60%) were women (Table 1).
Death occurred within 30 days of culture in 80 episodes (10.3%).
Infection due to a hypervirulent strain was associated with a higher
case fatality rate at day 30 as compared to infection caused by a
non-hypervirulent strain (20.7% vs. 8.5%; OR 2.8, 95% CI 1.6–4.8)
(Table 1). Those who died of CDI were signiﬁcantly older as
compared to those who survived (median 82 vs. 75 years,
p < 0.001). With regard to chronic conditions, atherosclerosis
was found to be associated with an increased case fatality in CDI
(11/45 vs. 8/112; OR 4.2, 95% CI 1.6–11.3, p = 0.003).
Infection due to a hypervirulent strain was associated with an
increased case fatality in patients aged <65 years and in those aged
65–74 years, but not in those aged >74 years (Table 2).
Hypervirulent strain type remained a signiﬁcant factor associated
with case fatality in the logistic regression model adjusted for gender
(Table 3).
3.1. Laboratory markers
Blood leukocytes, but not CRP or creatinine level predicted
infection due to a hypervirulent strain type. Plasma CRP level and
blood leukocyte count on the day of diagnosis (day of culture)
predicted case fatality (at day 30) in patients with CDI (Table 4).Table 4
Laboratory markers on the day Clostridium difﬁcile was detected (cultured) in






CRP, mg/l (n = 399) 106.0 (75–170.9) 79.4 (29.5–130.3) <0.001
Leukocytes, 109/l (n = 382) 13.2 (8.5–22.0) 9.6 (6.9–14.3) 0.009
Creatinine, mmol/l (n = 319) 74 (54–165) 60 (62–116) 0.629
Platelets, 109/l (n = 382) 262 (166–359) 270 (201–353) 0.759
CRP, C-reactive protein.4. Discussion
The ﬁndings presented here show a signiﬁcantly higher case
fatality associated with CDI due to a hypervirulent strain compared
to CDI associated with a non-hypervirulent strain. Although the
median age in those infected with a hypervirulent strain was
higher, the association between increased case fatality and
hypervirulent strain type retained its signiﬁcance when adjusted
for the effect of age in a logistic regression model. This study
showed that simple laboratory tests – CRP and leukocyte count –
are useful prognostic markers in CDI; blood leukocytes on the day
of diagnosis (positive culture) were signiﬁcantly higher in patients
infected with a hypervirulent strain type compared to those with
an infection due to a non-hypervirulent strain.
The case fatality rate in CDI found in the present study is in
accord with a recent report from Finland.8 It has previously been
shown that infection due to a hypervirulent C. difﬁcile strain type is
associated with increased mortality,5,6 although not all studies
have conﬁrmed this.2,7 Infection and colonization due to hyper-
virulent strain types have been shown to be strongly healthcare-
associated.12 Miller et al. showed that infection due to a
hypervirulent strain type was signiﬁcantly associated with
mortality in patients aged 60–90 years but not younger,6 and
that patients >90 years of age experience high rates of severe CDI,
regardless of strain type. Consistent with previous investigations,2
the present study showed that CDI is an infection predominantly
affecting the elderly. The present study indicated that patients
aged >74 years have a high case fatality rate in CDI regardless of
the strain type (Table 2).
Blood leukocytes were signiﬁcantly higher in patients infected
with a hypervirulent strain compared to patients infected with a
non-hypervirulent strain, whereas CRP, blood platelet count, and
creatinine levels did not differ between the types of infecting
strains. It has been shown that surface layer proteins from
C. difﬁcile induce inﬂammatory and regulatory cytokines in human
leukocytes.13 Recent data indicate that the surface layer protein A
variant of C. difﬁcile PCR ribotype 027 might contribute to its
clinical characteristics.14 The simple biological markers blood
leukocytes and CRP were valuable in predicting the outcome in
patients with C. difﬁcile infection. This ﬁnding is in accord with a
previous investigation showing the prognostic value of blood
leukocytes in CDI.15
Some limitations should be conceded here. Although there is a
diagnosis number for C. difﬁcile listed in the International
Classiﬁcation of Diseases 10th Revision (ICD-10), no speciﬁc
number for pseudomembranous colitis exists. This limits the
ability to retrospectively record all patients with CDI and those
with negative culture results despite obvious C. difﬁcile-associated
disease. The study was based solely on positive culture results and
we did not study hospital records regarding the clinical severity in
patients with a positive culture result. However, the present study
used the deﬁnition for C. difﬁcile-associated disease (CDAD)
introduced by the Society for Healthcare Epidemiology of America
(SHEA) and the Infectious Diseases Society of America (IDSA).16 In
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diarrhea, pseudomembranous colitis, or toxic megacolon, and no
asymptomatic patients are examined. This approach is in accord
with recently published practice guidelines for C. difﬁcile infection
in adults.16 The present ﬁndings represent the crude mortality
associated with culture-positive C. difﬁcile infection. Given the low
prevalence of asymptomatic C. difﬁcile carriers in the adult
population (3–4%),17 the potential number of those with no
C. difﬁcile-associated clinical disease in this material is low. As the
clinical signiﬁcance of C. difﬁcile in children is less certain,18 only
adult patients were included in the study. Cause-speciﬁc mortality
is difﬁcult to assess in patients with CDAD, and all-cause mortality
was taken as an endpoint in the present study. Due to the fact that
all patients with a positive C. difﬁcile culture in Pirkanmaa Hospital
District during the study period were included, there was no
possibility for selection bias and this study was population-based
by design. As CDI is predominantly an infection affecting the
elderly population, it may be difﬁcult to assess the independent
role of multiple comorbidities in patients with this condition. A
clear limitation of the present study was that the data on
underlying diseases were not available for all patients.
In conclusion, infection due to a hypervirulent strain and
advanced age are factors associated with increased case fatality in
CDI. Blood leukocytes were signiﬁcantly higher in episodes
associated with a hypervirulent strain, and leukocyte count and
CRP were found to be useful prognostic biomarkers in patients with
CDI.
Acknowledgements
This work was supported by a grant from the Medical Research
Fund of Tampere University Hospital. The funding source had no
involvement in the authors’ work.
Ethics: The study was a register-based retrospective study.
Study subjects were not contacted in this study. The laboratory
data were collected due to routine patient care and no additional
samples were taken from the study subjects for the study. The
study was approved by the medical director of Pirkanmaa Hospital
District. Neither patient consent nor the approval of the hospital
ethics board was required.
Conﬂict of interest: We declare that we do not have any conﬂicts
of interest.References
1. Kazakova SV, Ware K, Baughman B, Bilukha O, Paradis A, Sears S, et al. A hospital
outbreak of diarrhea due to an emerging epidemic strain of Clostridium difﬁcile.
Arch Intern Med 2006;166:2518–24.
2. Morgan OW, Rodrigues B, Elston T, Verlander NQ, Brown DF, Brazier J, et al.
Clinical severity of Clostridium difﬁcile PCR ribotype 027: a case–case study. PLoS
One 2008;3:e1812.
3. Khanna S, Pardi DS. The growing incidence and severity of Clostridium difﬁcile
infection in inpatient and outpatient settings. Expert Rev Gastroenterol Hepatol
2010;4:409–16.
4. O’Donoghue C, Kyne L. Update on Clostridium difﬁcile infection. Curr Opin
Gastroenterol 2011;27:38–47.
5. Hubert B, Loo VG, Bourgault AM, Poirier L, Dascal A, Fortin E, et al. A portrait of
the geographic dissemination of the Clostridium difﬁcile North American pulsed-
ﬁeld type 1 strain and the epidemiology of C. difﬁcile-associated disease in
Quebec. Clin Infect Dis 2007;44:238–44.
6. Miller M, Gravel D, Mulvey M, Taylor G, Boyd D, Simor A, et al. Health care-
associated Clostridium difﬁcile infection in Canada: patient age and infecting
strain type are highly predictive of severe outcome and mortality. Clin Infect Dis
2010;50:194–201.
7. Goorhuis A, Van der Kooi T, Vaessen N, Dekker FW, Van den Berg R, Harmanus C,
et al. Spread and epidemiology of Clostridium difﬁcile polymerase chain reaction
ribotype 027/toxinotype III in The Netherlands. Clin Infect Dis 2007;45:695–703.
8. Kotila SM, Virolainen A, Snellman M, Ibrahem S, Jalava J, Lyytikainen O.
Incidence, case fatality and genotypes causing Clostridium difﬁcile infections,
Finland, 2008. Clin Microbiol Infect 2011;17:888–93.
9. Ofﬁcial Statistics of Finland (OSF). Population structure. Helsinki: Statistics
Finland; 2011. Available at: http://www.stat.ﬁ/til/vrm_en.html (accessed Oc-
tober 2011).
10. Barbut F, Mastrantonio P, Delmee M, Brazier J, Kuijper E, Poxton I. Prospective
study of Clostridium difﬁcile infections in Europe with phenotypic and genotypic
characterisation of the isolates. Clin Microbiol Infect 2007;13: 1048–57.
11. Antikainen J, Pasanen T, Mero S, Tarkka E, Kirveskari J, Kotila S, et al. Detection of
virulence genes of Clostridium difﬁcile by multiplex PCR. APMIS 2009;117:607–13.
12. Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, Turgeon N, et al. Host
and pathogen factors for Clostridium difﬁcile infection and colonization. N Engl J
Med 2011;365:1693–703.
13. Ausiello CM, Cerquetti M, Fedele G, Spensieri F, Palazzo R, Nasso M, et al. Surface
layer proteins from Clostridium difﬁcile induce inﬂammatory and regulatory
cytokines in human monocytes and dendritic cells. Microbes Infect 2006;8:
2640–6.
14. Spigaglia P, Barbanti F, Mastrantonio P. Surface layer protein A variant of
Clostridium difﬁcile PCR-ribotype 027. Emerg Infect Dis 2011;17:317–9.
15. Pepin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, et al. Clostridi-
um difﬁcile-associated diarrhea in a region of Quebec from 1991 to 2003: a
changing pattern of disease severity. CMAJ 2004;171:466–72.
16. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical
practice guidelines for Clostridium difﬁcile infection in adults: 2010 update by the
Society for Healthcare Epidemiology of America (SHEA) and the Infectious Dis-
eases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431–55.
17. Bartlett JG, Perl TM. The new Clostridium difﬁcile—what does it mean? N Engl J
Med 2005;353:2503–5.
18. Enoch DA, Butler MJ, Pai S, Aliyu SH, Karas JA. Clostridium difﬁcile in children:
colonisation and disease. J Infect 2011;63:105–13.
